Bipolar Affective Disorder Current Episode Manic — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for bipolar affective disorder current episode manic. 405 active patents protecting 5 drugs from 5+ originators. First major cliff: 2026. Daily refresh.

5
Approved drugs
405
Active US patents
54/100
Avg vulnerability
$3.3B
Annual revenue covered

Originators in Bipolar Affective Disorder Current Episode Manic

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Otsuka/BMS) 214 patents Johnson & Johnson (Janssen) 110 patents Eli Lilly 56 patents Hisamitsu 18 patents Novartis AG (originally Geigy) 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating bipolar affective disorder current episode manic. Each bar = one year. Y-axis scaled to peak year (76 patents).

28
26
35
27
20
28
57
29
48
30
76
31
30
32
63
33
8
34
18
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Abilify
aripiprazole
 Generic (originally Otsuka/BMS) 214 61 $3.0B 2026-07-28
Risperdal
risperidone
 Johnson & Johnson (Janssen) 110 56 — 2026-06-26
Zyprexa
olanzapine
 Eli Lilly 56 64 $300M 2031-08-23
Saphris
ASENAPINE
 Hisamitsu 18 33 — 2033-07-25
Tegretol
carbamazepine
 Novartis AG (originally Geigy) 7 55 — 2028-11-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
8759350 Abilify method of use 85 2027-03-02
12194035 Zyprexa method of use 81 2031-08-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9119848 Zyprexa composition of matter 10 2031-08-30
9687474 Saphris formulation 25 2033-07-25
10022445 Saphris formulation 25 2033-07-25
10022445 Saphris formulation 25 2033-07-25
11123305 Saphris formulation 25 2033-07-25
9687474 Saphris formulation 25 2033-07-25
9687474 Saphris formulation 25 2033-07-25

Related